Acute Coronary Syndrome
Conditions
Keywords
Effectiveness study, Acute coronary Syndrome, Real-life, France
Brief summary
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
Detailed description
AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 130 Years
Healthy volunteers
No
Inclusion criteria
Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary. No
Exclusion criteria
.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Medical information | At baseline visit | History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors |
| Drug exposure | Current | Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Other medical events of interest | During follow-up (up to 12 months) | rMI, stroke, bleeding, death |
Countries
France
Outcome results
None listed